Oncology Articles

Patient Collaboration Can Help Solve
A factor contributing to better outcomes is better collaboration between physicians and their patients throughout the entire care process.
Anthony Accurso, MD, offers a patient more time managing their cancer and a better quality of life.
The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.
Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma
Investigators with the FDA’s Center for Drug Evaluation and Research and Oncology Center of Excellence conducted a pooled analysis of all trial reports and data marketing applications for the use of anti–PD-1 antibodies alone or in combination to treat patients with unresectable or metastatic melanoma. 
Pembrolizumab Plus SBRT Active in Advanced Solid Tumors
The addition of pembrolizumab to stereotactic body radiotherapy induced an objective response rate of 13.2% among patients with advanced solid tumors.
Expert Highlights Promising Research in mCRC and Other GI Cancers
Michael A. Morse, MD, discusses key trials that have broadened the treatment landscape of mCRC, and other ongoing developments in gastrointestinal cancers.
Immunotherapy Poised to Move Forward Into Stage III NSCLC
A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.
Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.
Findings Support Nab-Paclitaxel as Top Choice for First-Line TNBC Therapy
Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer. 
The FDA's Oncologic Drugs Advisory Committee is slated to review a supplemental biologics license application for the use of blinatumomab for the treatment of patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.
Publication Bottom Border
Border Publication